Evidence map›Paper›PMID 30572910›Full record

ArticleBreast cancer research : BCR2018

Prospective validation of the NCI Breast Cancer Risk Assessment Tool (Gail Model) on 40,000 Australian women.

Carolyn Nickson, Pietro Procopio, Louiza S Velentzis, Sarah Carr, Lisa Devereux, Gregory Bruce Mann, Paul James, Grant Lee, Cameron Wellard, Ian Campbell

Open access · goldAbstract readValidation Study
In one paragraph

Article in Breast cancer research : BCR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Cohort Profile: Lifepool.International journal of epidemiology · 2025
    Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Risk-Stratified Breast Cancer Screening in Malaysia: Challenges and Opportunities.Asian Pacific journal of cancer prevention : APJCP · 2024
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Carolyn NicksonMelbourne School of Population and Global Health, University of Melbourne, Carlton, Victoria, 3010, Australia. cnickson@unimelb.edu.au.ORCID 0000-0001-5370-6590
Pietro ProcopioMelbourne School of Population and Global Health, University of Melbourne, Carlton, Victoria, 3010, Australia.
Louiza S VelentzisMelbourne School of Population and Global Health, University of Melbourne, Carlton, Victoria, 3010, Australia.
Sarah CarrMelbourne School of Population and Global Health, University of Melbourne, Carlton, Victoria, 3010, Australia.
Lisa DevereuxLifepool Study, Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia.
Gregory Bruce MannBreast Service, Royal Women's and Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia.
Paul JamesSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, 3000, Australia.
Grant LeeMelbourne School of Population and Global Health, University of Melbourne, Carlton, Victoria, 3010, Australia.
Cameron WellardMelbourne School of Population and Global Health, University of Melbourne, Carlton, Victoria, 3010, Australia.
Ian CampbellSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, 3000, Australia.
The University of Melbourne · AUPeter MacCallum Cancer Centre · AUThe Royal Melbourne Hospital · AU

Funding

EPA EP-C-15-004
6 · The paper itself

Abstract

backgroundThere is a growing interest in delivering more personalised, risk-based breast cancer screening protocols. This requires population-level validation of practical models that can stratify women into breast cancer risk groups. Few studies have evaluated the Gail model (NCI Breast Cancer Risk Assessment Tool) in a population screening setting; we validated this tool in a large, screened population.

methodsWe used data from 40,158 women aged 50-69 years (via the lifepool cohort) participating in Australia's BreastScreen programme. We investigated the association between Gail scores and future invasive breast cancer, comparing observed and expected outcomes by Gail score ranked groups. We also used machine learning to rank Gail model input variables by importance and then assessed the incremental benefit in risk prediction obtained by adding variables in order of diminishing importance.

resultsOver a median of 4.3 years, the Gail model predicted 612 invasive breast cancers compared with 564 observed cancers (expected/observed (E/O) = 1.09, 95% confidence interval (CI) 1.00-1.18). There was good agreement across decile groups of Gail scores (χ

conclusionsThis study confirms that the Gail model (or a reduced model excluding information on hyperplasia and ethnicity) can effectively stratify a screened population aged 50-69 years according to the risk of future invasive breast cancer. This information has the potential to enable more personalised, risk-based screening strategies that aim to improve the balance of the benefits and harms of screening.

Indexed as

Models, StatisticalAgedArea Under CurveAustraliaBreast NeoplasmsEarly Detection of CancerFemaleHumansMass ScreeningMiddle AgedNational Cancer Institute (U.S.)Patient SelectionPrognosisProspective StudiesRisk AssessmentRisk FactorsBreast Cancer Risk Assessment ToolBreast cancer screeningGail modelInvasive breast cancerMachine learningRisk stratificationValidation

Identifiers

PMID30572910
PMCPMC6302513
OpenAlexW2903937587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.